Compare PLPC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | HROW |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2001 | N/A |
| Metric | PLPC | HROW |
|---|---|---|
| Price | $378.26 | $39.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $275.00 | $69.86 |
| AVG Volume (30 Days) | 85.4K | ★ 540.4K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.19 | $31.62 |
| Revenue Next Year | $7.28 | $50.77 |
| P/E Ratio | $54.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $151.11 | $28.54 |
| 52 Week High | $414.35 | $54.98 |
| Indicator | PLPC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.85 |
| Support Level | N/A | $37.03 |
| Resistance Level | N/A | $41.82 |
| Average True Range (ATR) | 0.00 | 2.18 |
| MACD | 0.00 | -0.53 |
| Stochastic Oscillator | 0.00 | 28.89 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. The Company's primary products support, protect, connect, terminate, and secure cables and wires. The Company provides helical solutions, connectors, fiber optic and copper splice closures, solar framing applications, and electric vehicle charging station foundations. The Company's customers include public and private energy utilities and communication companies, cable operators, contractors and subcontractors, distributors, and value-added resellers. Geographically, the company operates in four regions: PLP-USA, the Americas, EMEA, and Asia-Pacific.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.